Neurofibromatosis treatment granted orphan status by EMA
But trial in patients in early stage of the disease continues.
Immunotherapy takes on rivals from Roche and BMS.
No fast approval for immunotherapy combo in first line use.
Approval by May could put Keytruda in pole position
Companies end collaboration after more than 20 years.
FDA approvals could rebound in 2017 – but concerns about big pharma R&D productivity won’t go away.